NTRK2 and adenocarcinoma: Yin et al. [54] found that in triple-negative breast cancer, TrkB+ CSC play a key role in post-chemotherapy disease relapse, corroborating our findings and suggesting that in some adenocarcinomas, TrkB inhibition could disrupt this cell sub-population.